<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied the prevalence and clinical significance of anticardiolipin antibodies (aCL) in primary <z:hpo ids='HP_0002613'>biliary cirrhosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e>) and primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp> (PSC) as similar data are missing </plain></SENT>
<SENT sid="1" pm="."><plain>Ninety-nine <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e> patients, 41 PSC, 228 HCV, 50 HBV, 111 with other non-<z:mp ids='MP_0001799'>viral</z:mp> and non-autoimmune <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disorders</z:e> and 267 healthy were investigated </plain></SENT>
<SENT sid="2" pm="."><plain>In order to evaluate the avidity of aCL, <z:chebi fb="20" ids="16199">urea</z:chebi> 2 M was used </plain></SENT>
<SENT sid="3" pm="."><plain>IgG and/or IgM aCL were detected in 40% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e> and PSC patients, in 26.2% of disease controls (P &lt; 0.05) and 2.25% of healthy (P &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e>, IgG aCL associated with presence of <z:hpo ids='HP_0001394'>cirrhosis</z:hpo>, increased Mayo risk score and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, while in PSC with longer disease duration and biochemical activity </plain></SENT>
<SENT sid="5" pm="."><plain>Anti-beta2-GPI was detected in only three patients </plain></SENT>
<SENT sid="6" pm="."><plain>Both in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e> and PSC, resistance of aCL to <z:chebi fb="20" ids="16199">urea</z:chebi> was high, similar to that observed in <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="7" pm="."><plain>We demonstrated a significantly higher prevalence of aCL in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e> and PSC compared to <z:e sem="disease" ids="C0156194" disease_type="Disease or Syndrome" abbrv="">other liver diseases</z:e> and healthy </plain></SENT>
<SENT sid="8" pm="."><plain>aCL were associated with more severe disease in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e> and biochemical activity in PSC, but they rather seem to be "non-pathogenic" (co-factor-independent) </plain></SENT>
<SENT sid="9" pm="."><plain>However, their avidity was comparable with that of APS, indicating the need for prospective studies in order to address whether aCL in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e> and PSC may contribute to APS development or the progression of <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">hepatic disease</z:e> </plain></SENT>
</text></document>